FINWIRES · TerminalLIVE
FINWIRES

Update: Figma Shares Rise After Q1 Adjusted Net Income, Revenue Beat Estimates

By

(Updates with recent stock movement in headline and first paragraph.)

Figma (FIG) shares were up 14% in afternoon trading on Friday after the company posted Q1 adjusted net income and revenue that surpassed analysts' consensus.

The company reported Q1 adjusted net income late Thursday of $0.10 per diluted share, up from $0.03 a year earlier.

Analysts polled by FactSet expected $0.06.

Revenue for the three months ended March 31 rose to $333.4 million from $228.2 million a year earlier.

Analysts surveyed by FactSet expected $316 million.

The company expects fiscal Q2 revenue of $348 million to $350 million. Analysts expect $329.5 million.

The company expects full-year 2026 revenue of $1.42 billion to $1.43 billion, compared with $1.366 billion to $1.374 billion previously. Analysts expect $1.37 billion.

Price: $23.21, Change: $+2.97, Percent Change: +14.65%

Related Articles

Australia

Update: Xanadu Shares Fall After Q1 Loss Widens

(Updates with the latest stock move in the headline and the first paragraph.)Xanadu (XNDU) shares fell over 7% on Friday, a day after the company reported a wider Q1 loss.The company reported Thursday Q1 loss of $0.28 per diluted share, compared with a loss of $0.22 a year earlier.Revenue for the quarter ended March 31 was $2.8 million, up from $0.7 million a year ago.Two analysts surveyed by FactSet expected $1.1 million.Price: $14.00, Change: $-1.14, Percent Change: -7.50%

$XNDU
Australia

A. O. Smith Shares Drop After Downgrade From JPMorgan

A. O. Smith (AOS) shares were down 3.2% in afternoon trading on Friday after JPMorgan downgraded the company's stock to underweight from neutral and adjusted the price target to $60 from $65.Trading volume stood at more than 882,000 shares against a daily average of about 1.5 million.Price: $56.18, Change: $-1.79, Percent Change: -3.09%

$AOS
Australia

Top Midday Decliners

LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors to sell 2 million shares in a registered direct offering, targeting gross proceeds of about $20 million, the company said Friday.Shares sank 43% following an increase in intraday trading volume to almost 323,000 from a daily average of over 44,000.Aardvark Therapeutics (AARD) said the US Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101, according to a company statement late Thursday.Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.Shares of Aardvark slumped 31% as intraday trading volume advanced to more than 565,000 from a daily average of over 282,000.York Space Systems (YSS) reported a Q1 loss of $114.8 million, compared with a loss of $11.7 million a year earlier.Shares dropped 18%, with intraday trading volume at nearly 2.85 million, compared with a daily average of over 2.02 million.Price: $9.74, Change: $-7.41, Percent Change: -43.21%

$AARD$LNZA$YSS